Exothera

Activities: Manufacturing

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  2. CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
  3. ISPE announces 2024 Facility of the Year Awards category winners The awards programme recognises pharmaceutical companies that are the 'best' in the industry for innovation, operations, digitalisation, supply chain and social impact
  4. Tabletability, compactability and compressibility: What’s the difference? To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
  5. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

Manufacturing

Exothera expands continuous-batch RNA manufacturing into North America

Continuous-batch production of RNA service removes process development and scale-up steps through automation and significantly cuts clinical development time
Manufacturing

NIH selects Exothera for manufacturing of Covid intranasal vaccine

The CDMO Exothera has been selected by the National Institutes of Health to develop the manufacturing process for its intranasal vaccine against SARS-CoV-2
Drug Delivery

Exothera selected to develop a large-scale manufacturing process

The platform utilises a unique technology which creates electrostatic interactions between positively charged, tumour-specific peptides and the negatively charged surface of oncolytic adenoviruses
Research & Development

Vaccizone selects Exothera for process development and GMP manufacturing of its SARS‑CoV‑2 vaccine

Vaccizone, a vaccine development company focusing on innovative antigen delivery technology, selected Exothera S.A. to fast-track process development of its SARS‑CoV‑2 vaccine for European clinical trials
Manufacturing

Rokote selects Exothera for COVID vaccine manufacturing

The CDMO will be responsible for manufacturing clinical material of the intranasal vaccine for Phase I/II trials
Manufacturing

Exothera receives GMP certification in Belgium

The need to manufacture billions of vaccines, together with an expected 30 drug approvals by the FDA in the next year at least, will put immense pressure on global manufacturing capacity
Manufacturing

IDT Biologika enlists Exothera for viral vaccine scale-up

Exothera says it has successfully transferred IDT Biologika’s upstream process from small to large scale in the NevoLine Upstream platform (Univercells Technologies)
Subscribe now